Login to Your Account



Lux Closes $36M Series A, Signs Deal With Isotechnika

By Jennifer Boggs


Friday, May 26, 2006
At the same time that it closed its first significant financing round - a $36 million Series A - Lux Biosciences Inc. gained worldwide rights to a late-stage immunosuppressant drug from Isotechnika Inc. to develop for ophthalmic diseases. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription